Mereo BioPharma Group PLC (MREO)

Wow! O/S: 159,615,766 shares.
03/18/2026

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOApril 6, 2026 3:45 AM
PR Newswire (US)

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: June 5, 2023 to December 26, 2025DEADLINE: April 6, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302734436.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOMarch 30, 2026 3:42 AM
PR Newswire (US)

LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: June 5, 2023 to December 26, 2025DEADLINE: April 6, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302728373.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOMarch 23, 2026 3:26 AM
PR Newswire (US)

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: June 5, 2023 to December 26, 2025DEADLINE: April 6, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302721756.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOMarch 20, 2026 1:13 AM
PR Newswire (US)

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: June 5, 2023 to December 26, 2025DEADLINE: April 6, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302719436.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOMarch 12, 2026 4:19 AM
PR Newswire (US)

LOS ANGELES, March 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: June 5, 2023 to December 26, 2025DEADLINE: April 6, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302711857.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOMarch 2, 2026 3:52 AM
PR Newswire (US)

LOS ANGELES, March 2, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:  June 5, 2023 to December 26, 2025 DEADLINE: April 6, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302700592.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOFebruary 23, 2026 3:04 AM
PR Newswire (US)

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:  June 5, 2023 to December 26, 2025 DEADLINE: April 6, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302694306.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREOFebruary 12, 2026 3:00 PM
PR Newswire (US)

NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).







Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/mereo-biopharma-group-plc-loss-submission-form-5/?id=183521&from=4CLASS PERIOD: June 5, 2023 to December 26, 2025ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit its primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively.  On December 29, 2025, Mereo issued a press release announcing that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance. The press release indicated that neither study met its primary endpoint of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively, despite improved bone mineral density.   Following this news, the price of Mereo's ADS declined dramatically. From a closing market price of $2.31 per share on December 26, 2025, Mereo's ADS price fell to $0.29 per share on December 29, 2025, a decline of more than 87.7%.DEADLINE: April 6, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/mereo-biopharma-group-plc-loss-submission-form-5/?id=183521&from=4NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MREO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 6, 2026. There is no cost or obligation to you to participate in this case.WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg @bback



View original content to download multimedia:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations--investors-should-contact-the-gross-law-firm-before-april-6-2026-to-discuss-your-rights--mreo-302686703.htmlSOURCE The Gross Law Firm

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOFebruary 9, 2026 3:29 AM
PR Newswire (US)

LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:  June 5, 2023 to December 26, 2025 DEADLINE: April 6, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/mereo-biopharma-group-plc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--mreo-302682297.htmlSOURCE DJS Law Group LLP

Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MREOFebruary 6, 2026 7:30 AM
Business Wire
The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc (“Mereo” or “the Company”) (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.


Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.


CLASS PERIOD: June 5, 2023 to December 26, 2025


DEADLINE: April 6, 2026


CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo’s public statements were false and materially misleading throughout the class period.


If you are a shareholder who suffered a loss, contact us to participate.


WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.


Join the case to recover your losses.


This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260206087415/en/
David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com


Original: Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MREO

MREO...............................................https://stockcharts.com/sc3/ui/?s=MREO&p=w&b=5&g=0&id=p86431144783

MREO RUNNING TO A DOLLA

MREO.......................................P/M

Holy Jesus of Bethlehem, they’re gonna have to split this after they dilute it to death.

I hadda grabs me some o dis.

OUCH

MREO...............................................https://stockcharts.com/sc3/ui/?s=MREO&p=W&b=5&g=0&id=p86431144783

Double that by E.o.Y $$$$$$$$$

Here’s what matters( imho)

* As of June 30, 2024, the Company had cash and cash equivalents of $87.4 million, compared to $57.4 million as of December 31, 2023. This includes net proceeds of the $50 million underwritten registered direct offering priced at-the-market on June 14, 2024.
The Company expects, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses including pre-commercial activities for setrusum-ab, and capital expenditure requirements into 2027.

This guidance does not include any potential upfront payments associated with a partnership for alvelestat or business development activity around any of the Company's non-core programs.

The Company has two rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta (Ol) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-asso-ciated lung disease (AATD-LD). The Company's partner, Ultragenyx Pharmaceutical, Inc., has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 pediatric study in young adults (5 to 25 years old) for setrusumab in Ol and in the Phase 3 study in pediatric patients (2 to

MREO IS A MONTHY BULLISH BEAST...NO BETTER CHART OUT THERE AND THATS WHY 5.63 IS COMING

MREO BLOWING UP

MREO under $4

OPPS..PRETENDERS NEVER BUY NASDAQ STOCKS

MREO....READY TO BLAST TO 5.00

Here we go, $4 to be breached today??

http://archive.fast-edgar.com/20240612/AT22D22DZZ2R72ZZ2RJE2WYSQE79YZ22Z262

https://ih.advfn.com/p.php?pid=nmona&article=94024987

lol, thought you were..may want to , support and volume coming in..I’m also playn ur other fav, Fsrn…I think it can survive Bk..also buying TARA for mover to $30( currently under $3) GL :)

Never was in.

CJ, you still in this ticker??

Was trying to break $3.5-4ish, need some updated progress with P3 preliminary

MREO under $5

MREO 10Q due 4/3

MREO 10Q due 3/27

LMAO

Responding to this post???

Not sure why you keep posting to me on this stock I've never been in it..

Hey thanks

Fireside chat at 11:20am (est.)…stay tuned

Not sure why you keep posting to me on this stock I've never been in it..

Hey thanks

Watch and learn as we approach 5 bucks

MREO new 52 week high

WATCH AND LEARN

MREO...CAN'T HURT THIS STOCK!!!!

MREO..THE HOTTEST BIO OUT THERE

That’s a real big boy. Lmao.

Should drop to the 20 day @1.96. Run don’t walk out this piggy

I like it, but when it goes thru that, $5’s & $6’s by end of Q1 after some readouts!!( look at 5yr chart)

2.97 WEEKLY RESISTANCE BY EOM

Do we break $3 by e.o.m???

Fake grandchildren are so adorable

You don’t trade real stocks for some odd reason, lol…I know why fake granny, so you may fool all the stupid men on this site, but most men are pathetic and easy to lie to.

I'm not even trading this I'm not even sure why he's posting to me and like I said I could give him fat frogs ass what he says to me..

Lol

I’m gonna stay out of this ‘love’ affair and just say that technically, ‘fundamentally’ and the fact that we have Whales in this ticker, $5 is realistic in 2024!! GLTA ( especially U2, lol) :)